BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Argentiero A, De Summa S, Di Fonte R, Iacobazzi RM, Porcelli L, Da Vià M, Brunetti O, Azzariti A, Silvestris N, Solimando AG. Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers (Basel) 2019;11:E942. [PMID: 31277479 DOI: 10.3390/cancers11070942] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 15.0] [Reference Citation Analysis]
Number Citing Articles
1 Cho Y, Park MJ, Kim K, Park JY, Kim J, Kim W, Yoon JH. Tumor-Stroma Crosstalk Enhances REG3A Expressions that Drive the Progression of Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E472. [PMID: 31940813 DOI: 10.3390/ijms21020472] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Zhou X, Fan Y, He Y, Mou A, Wang F, Liu Y, Wu Z. Clinicopathological and Prognostic Value of Gastric Carcinoma Highly Expressed Transcript 1 in Cancer: A Meta-Analysis. J Oncol 2020;2020:6341093. [PMID: 32908508 DOI: 10.1155/2020/6341093] [Reference Citation Analysis]
3 Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A. Current Perspectives in Cancer Immunotherapy. Cancers (Basel) 2019;11:E1472. [PMID: 31575023 DOI: 10.3390/cancers11101472] [Cited by in Crossref: 64] [Cited by in F6Publishing: 52] [Article Influence: 21.3] [Reference Citation Analysis]
4 Solimando AG, Vacca A, Ribatti D. A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche. J Oncol 2020;2020:6820241. [PMID: 32508920 DOI: 10.1155/2020/6820241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Ribatti D, Solimando AG, Pezzella F. The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer. Cancers (Basel) 2021;13:3433. [PMID: 34298648 DOI: 10.3390/cancers13143433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Rim CH, Shin IS, Lee HY, Yoon WS, Park S. Oncologic Benefit of Adjuvant Chemoradiation after D2 Gastrectomy: A Stepwise Hierarchical Pooled Analysis and Systematic Review. Cancers (Basel) 2020;12:E2125. [PMID: 32751879 DOI: 10.3390/cancers12082125] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Speichinger F, Dragomir MP, Schallenberg S, Loch FN, Degro CE, Baukloh AK, Hartmann L, Pozios I, Schineis C, Margonis GA, Lauscher JC, Beyer K, Kamphues C. Rethinking the TNM Classification Regarding Direct Lymph Node Invasion in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;14:201. [PMID: 35008365 DOI: 10.3390/cancers14010201] [Reference Citation Analysis]
8 Argentiero A, Calabrese A, Sciacovelli AM, Delcuratolo S, Solimando AG, Brunetti O. Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. Can J Gastroenterol Hepatol 2020;2020:8679751. [PMID: 33102398 DOI: 10.1155/2020/8679751] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Vuijk FA, de Muynck LDAN, Franken LC, Busch OR, Wilmink JW, Besselink MG, Bonsing BA, Bhairosingh SS, Kuppen PJK, Mieog JSD, Sier CFM, Vahrmeijer AL, Verheij J, Fariňa-Sarasqueta A, Swijnenburg RJ. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Sci Rep 2020;10:16211. [PMID: 33004930 DOI: 10.1038/s41598-020-73242-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Topi S, Santacroce L, Bottalico L, Ballini A, Inchingolo AD, Dipalma G, Charitos IA, Inchingolo F. Gastric Cancer in History: A Perspective Interdisciplinary Study. Cancers (Basel) 2020;12:E264. [PMID: 31978985 DOI: 10.3390/cancers12020264] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
11 Bintz J, Abuelafia AM, Gerbe F, Baudoin E, Auphan-Anezin N, Sidot E, Jay P, Iovanna J. Expression of POU2F3 Transcription Factor Control Inflammation, Immunological Recruitment and Metastasis of Pancreatic Cancer in Mice. Biology (Basel) 2020;9:E341. [PMID: 33086657 DOI: 10.3390/biology9100341] [Reference Citation Analysis]
12 Diotaiuti S, De Summa S, Altieri R, Dantona C, Tommasi S, Di Gennaro M, Rubini G, Pastena MI, Argentiero A, Zito FA, Silvestris N, Paradiso AV. Biomarker phenotyping drives clinical management in axillary sentinel node: A retrospective study on women with primary breast cancer in 2002. Oncol Lett 2020;20:2469-76. [PMID: 32782565 DOI: 10.3892/ol.2020.11793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Shimomura H, Okada R, Tanaka T, Hozaka Y, Wada M, Moriya S, Idichi T, Kita Y, Kurahara H, Ohtsuka T, Seki N. Role of miR-30a-3p Regulation of Oncogenic Targets in Pancreatic Ductal Adenocarcinoma Pathogenesis. Int J Mol Sci 2020;21:E6459. [PMID: 32899691 DOI: 10.3390/ijms21186459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lu J, Wei S, Lou J, Yin S, Zhou L, Zhang W, Zheng S. Systematic Analysis of Alternative Splicing Landscape in Pancreatic Adenocarcinoma Reveals Regulatory Network Associated with Tumorigenesis and Immune Response. Med Sci Monit 2020;26:e925733. [PMID: 32706768 DOI: 10.12659/MSM.925733] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Odagiri N, Hai H, Thuy LTT, Dong MP, Suoh M, Kotani K, Hagihara A, Uchida-Kobayashi S, Tamori A, Enomoto M, Kawada N. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. Cancers (Basel) 2020;12:E2045. [PMID: 32722224 DOI: 10.3390/cancers12082045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
17 Estaras M, Gonzalez-Portillo MR, Fernandez-Bermejo M, Mateos JM, Vara D, Blanco-Fernandez G, Lopez-Guerra D, Roncero V, Salido GM, González A. Melatonin Induces Apoptosis and Modulates Cyclin Expression and MAPK Phosphorylation in Pancreatic Stellate Cells Subjected to Hypoxia. Int J Mol Sci 2021;22:5555. [PMID: 34074034 DOI: 10.3390/ijms22115555] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Anania S, Peiffer R, Rademaker G, Hego A, Thiry M, Deldicque L, Francaux M, Maloujahmoum N, Agirman F, Bellahcène A, Castronovo V, Peulen O. Myoferlin Is a Yet Unknown Interactor of the Mitochondrial Dynamics' Machinery in Pancreas Cancer Cells. Cancers (Basel) 2020;12:E1643. [PMID: 32575867 DOI: 10.3390/cancers12061643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Ahangar NK, Hemmat N, Khalaj-Kondori M, Shadbad MA, Sabaie H, Mokhtarzadeh A, Alizadeh N, Derakhshani A, Baghbanzadeh A, Dolatkhah K, Silvestris N, Baradaran B. The Regulatory Cross-Talk between microRNAs and Novel Members of the B7 Family in Human Diseases: A Scoping Review. Int J Mol Sci 2021;22:2652. [PMID: 33800752 DOI: 10.3390/ijms22052652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Krog RT, de Miranda NFCC, Vahrmeijer AL, Kooreman NG. The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:5789. [PMID: 34830945 DOI: 10.3390/cancers13225789] [Reference Citation Analysis]
21 Hua YQ, Zhang K, Sheng J, Ning ZY, Li Y, Shi WD, Liu LM. Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway. Life Sci 2021;:119205. [PMID: 33571515 DOI: 10.1016/j.lfs.2021.119205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Bai R, Li L, Chen X, Chen N, Song W, Zhang Y, Lv Z, Han F, Zhao Y, Li W, Cui J. Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors. J Oncol 2021;2021:9935076. [PMID: 34335763 DOI: 10.1155/2021/9935076] [Reference Citation Analysis]
23 Mancarella S, Krol S, Crovace A, Leporatti S, Dituri F, Frusciante M, Giannelli G. Validation of Hepatocellular Carcinoma Experimental Models for TGF-β Promoting Tumor Progression. Cancers (Basel) 2019;11:E1510. [PMID: 31600917 DOI: 10.3390/cancers11101510] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
24 Florio R, Veschi S, di Giacomo V, Pagotto S, Carradori S, Verginelli F, Cirilli R, Casulli A, Grassadonia A, Tinari N, Cataldi A, Amoroso R, Cama A, De Lellis L. The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer. Cancers (Basel) 2019;11:E2042. [PMID: 31861153 DOI: 10.3390/cancers11122042] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
25 Solimando AG, Annese T, Tamma R, Ingravallo G, Maiorano E, Vacca A, Specchia G, Ribatti D. New Insights into Diffuse Large B-Cell Lymphoma Pathobiology. Cancers (Basel) 2020;12:E1869. [PMID: 32664527 DOI: 10.3390/cancers12071869] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
26 Zhao X, Cao D, Ren Z, Liu Z, Lv S, Zhu J, Li L, Lang R, He Q. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma. Biosci Rep 2020;40:BSR20200214. [PMID: 32701143 DOI: 10.1042/BSR20200214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Mehta M, Malyla V, Paudel KR, Chellappan DK, Hansbro PM, Oliver BG, Dua K. Berberine loaded liquid crystalline nanostructure inhibits cancer progression in adenocarcinomic human alveolar basal epithelial cells in vitro. J Food Biochem 2021;45:e13954. [PMID: 34609010 DOI: 10.1111/jfbc.13954] [Reference Citation Analysis]
28 Geismann C, Schäfer H, Gundlach JP, Hauser C, Egberts JH, Schneider G, Arlt A. NF-κB Dependent Chemokine Signaling in Pancreatic Cancer. Cancers (Basel) 2019;11:E1445. [PMID: 31561620 DOI: 10.3390/cancers11101445] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
29 Liu C, Li Y, Zhang L, Zhang P, Yu N, Liu X, Lu H, Du H, Hou S, Kang Z. MiRNA-196-5p Promotes Proliferation and Migration in Cholangiocarcinoma via HAND1/Wnt/β-Catenin Signaling Pathway. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/4599676] [Reference Citation Analysis]
30 Chen H, Zu F, Zeng T, Chen Z, Wei J, Liu P, Li Z, Zhou L, Wang H, Tan H, Tan X. Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer. Front Oncol 2022;11:757791. [DOI: 10.3389/fonc.2021.757791] [Reference Citation Analysis]
31 Argentiero A, Calabrese A, Solimando AG, Notaristefano A, Panarelli MMG, Brunetti O. Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. Clin Case Rep 2019;7:1972-6. [PMID: 31624620 DOI: 10.1002/ccr3.2412] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Solimando AG, Summa S, Vacca A, Ribatti D. Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling. Cancers (Basel) 2020;12:E3380. [PMID: 33203154 DOI: 10.3390/cancers12113380] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
33 Martinson HA, Mallari D, Richter C, Wu TT, Tiesinga J, Alberts SR, Olnes MJ. Molecular Classification of Gastric Cancer among Alaska Native People. Cancers (Basel) 2020;12:E198. [PMID: 31941061 DOI: 10.3390/cancers12010198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
34 Gregório C, Soares-Lima SC, Alemar B, Recamonde-Mendoza M, Camuzi D, de Souza-Santos PT, Rivero R, Machado S, Osvaldt A, Ashton-Prolla P, Pinto LFR. Calcium Signaling Alterations Caused by Epigenetic Mechanisms in Pancreatic Cancer: From Early Markers to Prognostic Impact. Cancers (Basel) 2020;12:E1735. [PMID: 32629766 DOI: 10.3390/cancers12071735] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
35 Hosseinkhani N, Derakhshani A, Kooshkaki O, Abdoli Shadbad M, Hajiasgharzadeh K, Baghbanzadeh A, Safarpour H, Mokhtarzadeh A, Brunetti O, Yue SC, Silvestris N, Baradaran B. Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies? Int J Mol Sci 2020;21:E8305. [PMID: 33167514 DOI: 10.3390/ijms21218305] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
36 Dókus LE, Lajkó E, Ranđelović I, Mező D, Schlosser G, Kőhidai L, Tóvári J, Mező G. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer. Pharmaceutics 2020;12:E576. [PMID: 32580307 DOI: 10.3390/pharmaceutics12060576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Ono A, Aikata H, Yamauchi M, Kodama K, Ohishi W, Kishi T, Ohya K, Teraoka Y, Osawa M, Fujino H, Nakahara T, Murakami E, Miki D, Kawaoka T, Abe-Chayama H, Zhang P, Liu S, Makokha GN, Tsuge M, Imamura M, Hayes CN, Chayama K. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. Ther Adv Med Oncol 2020;12:1758835920922051. [PMID: 32547646 DOI: 10.1177/1758835920922051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
38 Zhou L, Wang H, Zhong M, Fang Z, Le Y, Nie F, Zhou J, Xiong J, Xiang X, Fang Z, Silvestris N. The E3 Ubiquitin Ligase TRIM11 Facilitates Gastric Cancer Progression by Activating the Wnt/β-Catenin Pathway via Destabilizing Axin1 Protein. Journal of Oncology 2022;2022:1-14. [DOI: 10.1155/2022/8264059] [Reference Citation Analysis]
39 Ding F, Hong X, Fan X, Huang S, Lian W, Chen X, Liu Q, Chen Y, Gao F. DDIT4 Novel Mutations in Pancreatic Cancer. Gastroenterol Res Pract 2021;2021:6674404. [PMID: 34007269 DOI: 10.1155/2021/6674404] [Reference Citation Analysis]
40 Yang MH, Chen M, Mo HH, Tsai WC, Chang YC, Chang CC, Chen KC, Wu HY, Yuan CH, Lee CH, Chen YA, Tyan YC. Utilizing Experimental Mouse Model to Identify Effectors of Hepatocellular Carcinoma Induced by HBx Antigen. Cancers (Basel) 2020;12:E409. [PMID: 32050622 DOI: 10.3390/cancers12020409] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
41 Lin K, Zhu J, Hu C, Bu F, Luo C, Zhu X, Zhu Z. Comprehensive analysis of the prognosis for chromobox family in gastric cancer. J Gastrointest Oncol 2020;11:932-51. [PMID: 33209489 DOI: 10.21037/jgo-20-208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Hosseinkhani N, Derakhshani A, Shadbad MA, Argentiero A, Racanelli V, Kazemi T, Mokhtarzadeh A, Brunetti O, Silvestris N, Baradaran B. The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Front Immunol 2021;12:676181. [PMID: 34093577 DOI: 10.3389/fimmu.2021.676181] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Gan LL, Hii LW, Wong SF, Leong CO, Mai CW. Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. Cancers (Basel) 2020;12:E1872. [PMID: 32664564 DOI: 10.3390/cancers12071872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
44 Sadozai H, Acharjee A, Gruber T, Gloor B, Karamitopoulou E. Pancreatic Cancers with High Grade Tumor Budding Exhibit Hallmarks of Diminished Anti-Tumor Immunity. Cancers (Basel) 2021;13:1090. [PMID: 33806316 DOI: 10.3390/cancers13051090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Do M, Kim H, Shin D, Park J, Kim H, Han Y, Jang JY, Kim Y. Marker Identification of the Grade of Dysplasia of Intraductal Papillary Mucinous Neoplasm in Pancreatic Cyst Fluid by Quantitative Proteomic Profiling. Cancers (Basel) 2020;12:E2383. [PMID: 32842508 DOI: 10.3390/cancers12092383] [Reference Citation Analysis]
46 Argentiero A, Solimando AG, Krebs M, Leone P, Susca N, Brunetti O, Racanelli V, Vacca A, Silvestris N. Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. J Clin Med 2020;9:E1594. [PMID: 32456352 DOI: 10.3390/jcm9051594] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
47 Xu C, Sui S, Shang Y, Yu Z, Han J, Zhang G, Ntim M, Hu M, Gong P, Chen H, Zhang X. The landscape of immune cell infiltration and its clinical implications of pancreatic ductal adenocarcinoma. J Adv Res 2020;24:139-48. [PMID: 32322419 DOI: 10.1016/j.jare.2020.03.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
48 Argentiero A, Solimando AG, Brunetti O, Calabrese A, Pantano F, Iuliani M, Santini D, Silvestris N, Vacca A. Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. Cancers (Basel) 2019;11:E1270. [PMID: 31470608 DOI: 10.3390/cancers11091270] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
49 Liu R, Liao YZ, Zhang W, Zhou HH. Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes. Front Oncol 2020;10:575264. [PMID: 33489882 DOI: 10.3389/fonc.2020.575264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
50 Saha SK, Biswas PK, Gil M, Cho SG. High Expression of TTYH3 is Related to Poor Clinical Outcomes in Human Gastric Cancer. J Clin Med 2019;8:E1762. [PMID: 31652813 DOI: 10.3390/jcm8111762] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
51 Longo V, Brunetti O, Gnoni A, Licchetta A, Delcuratolo S, Memeo R, Solimando AG, Argentiero A. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Medicina (Kaunas) 2019;55:E698. [PMID: 31627433 DOI: 10.3390/medicina55100698] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
52 Sudo H, Tsuji AB, Sugyo A, Kurosawa G, Kurosawa Y, Alexander D, Tsuda H, Saga T, Higashi T. Radiolabeled Human Monoclonal Antibody 067-213 has the Potential for Noninvasive Quantification of CD73 Expression. Int J Mol Sci 2020;21:E2304. [PMID: 32225110 DOI: 10.3390/ijms21072304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Mo J, Hu X, Gu L, Chen B, Khadaroo PA, Shen Z, Dong L, Lv Y, Chitumba MN, Liu J. Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. World J Surg Oncol 2020;18:15. [PMID: 31959178 DOI: 10.1186/s12957-020-1792-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
54 Zhang X, Li X, Xie J, Zhu Q, Yuan Y. A Novel Immune-Related Prognostic Signature Predicting Survival in Patients with Pancreatic Adenocarcinoma. J Oncol 2022;2022:8909631. [PMID: 35342420 DOI: 10.1155/2022/8909631] [Reference Citation Analysis]
55 Tang F, Dai P, Wei Q, Gan K, Wang Z, Chen H, Li T, Lv M, Deng M, Luo G. The Neutrophil-to-Monocyte Ratio and Platelet-to-White Blood Cell Ratio Represent Novel Prognostic Markers in Patients with Pancreatic Cancer. Gastroenterol Res Pract 2021;2021:6693028. [PMID: 34122538 DOI: 10.1155/2021/6693028] [Reference Citation Analysis]